Analytical Data
-
Gene name
MCR-1
- Application
-
Alternative Names
Polymyxin resistance protein MCR-1
-
Species
Escherichia coli
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A0R6L508
-
Expression Region
1-541aa
-
Molecular Weight
76.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MCR-1 (mobilized colistin resistance-1) is a plasmid-mediated gene that confers resistance to colistin, one of the last-resort antibiotics used to treat multidrug-resistant Gram-negative infections. First identified in Enterobacteriaceae in 2015, MCR-1 represents a significant public health threat as it facilitates the spread of colistin resistance among various bacterial species, complicating treatment options for severe infections. The gene encodes a phosphoethanolamine transferase, which modifies the lipid A component of lipopolysaccharides in the bacterial membrane, thereby reducing the binding affinity of colistin. The emergence of MCR-1 and its subsequent variants highlights the urgent need for genomic surveillance, as well as the development of alternative therapeutic strategies. Research into MCR-1 involves understanding its mechanisms of resistance, assessing its prevalence in clinical and environmental isolates, and exploring the potential for plasmid co-carriage with other resistance genes. The implications of MCR-1 extend beyond individual patient care, as its presence in the microbiome and food supply underscores the complexity of antibiotic resistance as a global public health concern. Scientists are focused on elucidating the genetic and biochemical pathways involved in MCR-1 function and propagation, which may guide the design of novel inhibitors or alternative therapeutic options. Given the critical role of colistin in treating infections caused by carbapenem-resistant bacteria, ongoing research into MCR-1 is vital for addressing the rising tide of antibiotic resistance and safeguarding the efficacy of existing antibiotics.
